Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $44,892.17 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,499 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total value of $44,892.17. Following the sale, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.04, for a total value of $16,699.48.
• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $12.78 on Friday. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $18.12. The business has a 50-day moving average of $13.86 and a 200-day moving average of $9.92.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The firm had revenue of $16.59 million during the quarter, compared to the consensus estimate of $14.58 million. As a group, analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its holdings in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $59,000. International Assets Investment Management LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $1,175,000. Jump Financial LLC acquired a new position in Nurix Therapeutics in the fourth quarter worth about $158,000. Finally, Principal Financial Group Inc. increased its holdings in Nurix Therapeutics by 14.8% in the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock valued at $122,000 after buying an additional 2,002 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NRIX. Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. HC Wainwright cut their price objective on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Royal Bank of Canada upped their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. Finally, Morgan Stanley increased their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.